GANX

Gain Therapeutics (GANX)

Gain Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:GANX

1 2 3 4 5 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/30	20 : 00	GlobeNewswire Inc.	Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024	NASDAQ:GANX	Gain Therapeutics Inc
2024/05/15	05 : 06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:GANX	Gain Therapeutics Inc
2024/05/15	05 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GANX	Gain Therapeutics Inc
2024/05/14	20 : 30	GlobeNewswire Inc.	Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update	NASDAQ:GANX	Gain Therapeutics Inc
2024/04/24	22 : 25	GlobeNewswire Inc.	Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease	NASDAQ:GANX	Gain Therapeutics Inc
2024/04/08	22 : 25	GlobeNewswire Inc.	Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer	NASDAQ:GANX	Gain Therapeutics Inc
2024/04/01	22 : 25	GlobeNewswire Inc.	Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer	NASDAQ:GANX	Gain Therapeutics Inc
2024/03/26	21 : 00	GlobeNewswire Inc.	Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update	NASDAQ:GANX	Gain Therapeutics Inc
2024/03/16	03 : 30	GlobeNewswire Inc.	Gain Therapeutics to Present at Public Ventures Discovery Day	NASDAQ:GANX	Gain Therapeutics Inc
2024/03/05	22 : 00	GlobeNewswire Inc.	Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease	NASDAQ:GANX	Gain Therapeutics Inc
2024/02/28	04 : 00	GlobeNewswire Inc.	Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease	NASDAQ:GANX	Gain Therapeutics Inc
2024/02/22	21 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GANX	Gain Therapeutics Inc
2024/02/15	02 : 29	GlobeNewswire Inc.	Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight	NASDAQ:GANX	Gain Therapeutics Inc
2024/02/06	23 : 56	GlobeNewswire Inc.	UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease	NASDAQ:GANX	Gain Therapeutics Inc
2024/02/06	22 : 00	GlobeNewswire Inc.	Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease	NASDAQ:GANX	Gain Therapeutics Inc
2024/02/01	07 : 26	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GANX	Gain Therapeutics Inc
2024/01/31	22 : 00	GlobeNewswire Inc.	Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update	NASDAQ:GANX	Gain Therapeutics Inc
2024/01/03	06 : 09	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:GANX	Gain Therapeutics Inc
2024/01/02	22 : 00	GlobeNewswire Inc.	Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024	NASDAQ:GANX	Gain Therapeutics Inc
2024/01/02	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:GANX	Gain Therapeutics Inc
2023/12/20	06 : 52	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:GANX	Gain Therapeutics Inc
2023/12/01	22 : 00	GlobeNewswire Inc.	Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/29	22 : 00	GlobeNewswire Inc.	Gain Therapeutics to Participate in AI Driven Drug Discovery Summit	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/25	03 : 01	GlobeNewswire Inc.	Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/24	20 : 07	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/23	07 : 27	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/21	22 : 54	GlobeNewswire Inc.	Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/21	06 : 22	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/21	06 : 03	GlobeNewswire Inc.	Gain Therapeutics Announces Proposed Public Offering	NASDAQ:GANX	Gain Therapeutics Inc
2023/11/18	06 : 27	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:GANX	Gain Therapeutics Inc